Morningstar Reports Strong Q1 2026 Results with 50% EPS Growth, $300M Share Buyback, and CRSP Acquisition Details
MORN sits 26% above its 52-week low of $149.08.
Summary
Morningstar reported strong first-quarter 2026 financial results, including double-digit revenue growth and a 50% increase in diluted EPS, alongside a $300 million share repurchase and details on the CRSP acquisition.
Key Events · Earnings and Guidance · MORN
-
Strong Q1 2026 Financial Performance
Revenue increased 10.8% to $644.8 million, operating income rose 36.6% to $155.9 million, and diluted EPS surged 50.0% to $2.73 compared to Q1 2025.
-
Substantial Share Repurchase
The company repurchased 1,723,412 shares for $300.0 million during Q1 2026, with $400.0 million remaining under the $1.0 billion program.
-
CRSP Acquisition Details
Morningstar completed the acquisition of CRSP for $363.0 million in cash on February 2, 2026, which was financed through the 2025 Credit Agreement and contributed to a significant increase in long-term debt.
-
Increased Long-Term Debt
Total long-term debt increased by $622.0 million to $1,694.6 million as of March 31, 2026, primarily due to financing the CRSP acquisition and general corporate purposes.
Analysis · MORN · Finance
Morningstar's Q1 2026 results demonstrate robust financial health with significant year-over-year growth in revenue, operating income, and diluted EPS. The company executed a substantial share repurchase program, returning capital to shareholders. The detailed financials also reveal the financing structure for the recent CRSP acquisition, which contributed to a notable increase in long-term debt. Investors should monitor the integration of CRSP and the impact of increased leverage on future financial flexibility.
At the time of this filing, MORN was trading at $187.60 on NASDAQ in the Finance sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $149.08 to $316.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.